BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31263891)

  • 41. The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination.
    Abu Raya B; Srugo I; Kessel A; Peterman M; Bader D; Peri R; Ashtamker N; Gonen R; Bamberger E
    Vaccine; 2014 Sep; 32(43):5632-7. PubMed ID: 25148774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data.
    Marchal C; Belhassen M; Guiso N; Jacoud F; Van Ganse E; Le Pannerer M; Cohen R; Verdier R; Uhart M
    Vaccine; 2021 Jan; 39(3):505-511. PubMed ID: 33357956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Knowledge, attitudes, beliefs and practices of obstetrics-gynecologists on seasonal influenza and pertussis immunizations in pregnant women: preliminary results from North-Western Italy.
    Ricco' M; Vezzosi L; Gualerzi G; Balzarini F; Capozzi VA; Volpi L
    Minerva Ginecol; 2019 Aug; 71(4):288-297. PubMed ID: 30938116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital.
    Jiang C; Whitmore-Sisco L; Gaur AH; Adderson EE;
    Vaccine; 2018 Jan; 36(2):214-219. PubMed ID: 29217370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
    McAlister SM; van den Biggelaar AHJ; Woodman TL; Hutton H; Thornton RB; Richmond PC
    Vaccine; 2021 Mar; 39(11):1642-1651. PubMed ID: 33589299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults.
    Weston WM; Chandrashekar V; Friedland LR; Howe B
    Hum Vaccin; 2009 Dec; 5(12):858-66. PubMed ID: 19838080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.
    Hanvatananukul P; Prasarakee C; Sarachai S; Aurpibul L; Sintupat K; Khampan R; Saheng J; Sudjaritruk T
    Int J Infect Dis; 2020 Jul; 96():422-430. PubMed ID: 32387447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
    Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
    Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
    Blatter M; Friedland LR; Weston WM; Li P; Howe B
    Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants.
    Healy CM; Rench MA; Baker CJ
    Clin Infect Dis; 2013 Feb; 56(4):539-44. PubMed ID: 23097585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
    Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
    van der Lee S; van Rooijen DM; de Zeeuw-Brouwer ML; Bogaard MJM; van Gageldonk PGM; Marinovic AB; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():681. PubMed ID: 29670634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination.
    Tanriover MD; Soyler C; Ascioglu S; Cankurtaran M; Unal S
    Eur J Intern Med; 2014 Jul; 25(6):528-32. PubMed ID: 24814432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
    Perrett KP; Halperin SA; Nolan T; Carmona Martínez A; Martinón-Torres F; García-Sicilia J; Virta M; Vanderkooi OG; Zuccotti GV; Manzoni P; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Stranak Z; Merino Arribas JM; Cilleruelo Ortega MJ; Miranda-Valdivieso M; Arias Novas B; Ramos Amador JT; Omeñaca F; Baca M; Marchisio PG; Mesaros N
    Vaccine; 2020 Feb; 38(8):2105-2114. PubMed ID: 31776027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.